[Current status and prospects of clinical practice for arteriovenous graft in China]

The use of arteriovenous graft (AVG) fails to meet the clinical needs in China, although it is recommended by guidelines to be the alternative access for maintenance hemodialysis (MHD) patients. Patency and complication incidence of AVG reported by recent research is superior to traditional cognition, and thus AVG should be one of main types of access in our country. Personalized selection of proper patients and grafts may improve the outcomes of AVG. In the future, outcomes of AVG must be further improved by clinical research with accurate personalized selection, basic research of precise molecule target and innovation of graft materials.